Sangamo Therapeutics Ownership | Who Owns Sangamo Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Sangamo Therapeutics Ownership Summary


Sangamo Therapeutics is owned by 25.83% institutional investors, 1.77% insiders, and 72.41% retail investors. Armistice capital is the largest institutional shareholder, holding 11.96% of SGMO shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.51% of its assets in Sangamo Therapeutics shares.

SGMO Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockSangamo Therapeutics25.83%1.77%72.41%
SectorHealthcare Stocks 35.74%11.83%52.43%
IndustryBiotech Stocks 36.05%11.82%52.13%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Armistice capital40.40M11.96%$9.97M
Vanguard group12.00M3.94%$5.04M
Blackrock4.70M2.61%$1.69M
Two sigma investments, lp6.27M1.86%$1.55M
Balyasny asset management5.29M1.57%$1.31M
Geode capital management4.57M1.35%$1.13M
Blackrock funding, inc. /de4.55M1.35%$1.12M
Renaissance3.84M1.14%$947.27K
Two sigma advisers, lp2.11M0.82%$1.42M
Ubs group2.57M0.76%$635.03K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Luminus management1.68M0.25%$415.06K
Armistice capital40.40M0.18%$9.97M
Hedges asset management125.00K0.04%$52.50K
Sanders morris harris668.00K0.03%$164.93K
Wealth management associates295.80K0.03%$73.03K
Ikarian capital1.22M0.02%$300.89K
Diametric capital, lp353.48K0.02%$87.27K
Mak capital one561.54K0.02%$138.64K
R squared89.87K0.01%$22.19K
Meritage portfolio management227.00K0.01%$95.34K

Top Buyers

HolderShares% AssetsChange
Armistice capital40.40M0.18%40.40M
Balyasny asset management5.29M0.00%5.29M
Vanguard fiduciary trust2.31M0.00%2.31M
Ubs group2.57M0.00%1.55M
Two sigma investments, lp6.27M0.00%1.51M

Top Sellers

HolderShares% AssetsChange
Blackrock4.70M--8.57M
Renaissance3.84M0.00%-4.59M
Acadian asset management---4.56M
Jane street group---2.92M
Point72 asset management---2.00M

New Positions

HolderShares% AssetsChangeValue
Armistice capital40.40M0.18%40.40M$9.97M
Balyasny asset management5.29M0.00%5.29M$1.31M
Vanguard fiduciary trust2.31M0.00%2.31M$570.64K
Mak capital one561.54K0.02%561.54K$138.64K
Marshall wace, llp303.86K0.00%303.86K$75.97K

Sold Out

HolderChange
Barclays-1.00
Headlands-5.00
Srs capital advisors-31.00
Td waterhouse canada-31.00
Gps wealth strategies group-100.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026102-8.11%87,227,22440.09%256.17%5118.60%14-58.82%
Dec 31, 202537-68.91%15,567,844-75.13%50.86%15-72.73%8-60.00%
Sep 30, 202543-61.95%19,880,715-60.46%72.02%17-63.83%7-75.86%
Jun 30, 2025118-9.92%51,227,326-2.55%193.50%47-16.07%32-5.88%
Mar 31, 2025130-4.41%52,338,132-14.91%232.73%55-22.54%349.68%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF5.65M2.51%1.00
Wasatch Ultra Growth5.59M2.28%1.06M
Vanguard Total Stock Mkt Idx Inv7.96M1.92%-
SPDR® S&P Biotech ETF3.73M1.75%-22.75K
Wasatch Micro Cap2.34M1.12%-3.31M
Vanguard Institutional Extnd Mkt Idx Tr4.46M1.08%-
Vanguard Strategic Small-Cap Equity Inv1.71M0.82%-
Vanguard Explorer Inv1.40M0.67%-
Fidelity Extended Market Index2.10M0.51%321.57K
Schwab US Small-Cap ETF™1.80M0.43%-131.00

Recent Insider Transactions


DateNameRoleActivityValue
Apr 22, 2026Davis Gregory D Head of Research & TechnologySell$17.69K
Apr 21, 2026Dubois-Stringfellow Nathalie SVP-CHIEF DEVELOPMENT OFFICERSell$89.18K
Sep 26, 2023BIOGEN INC.-Sell$3.00M
Aug 29, 2022BIOGEN INC.-Sell$2.13M
Aug 29, 2022Biogen MA Inc. Sell$526.52K

Insider Transactions Trends


DateBuySell
2026 Q2-2
2026 Q1--
2025 Q4--
2025 Q3--
2025 Q2--

SGMO Ownership FAQ


Who Owns Sangamo Therapeutics?

Sangamo Therapeutics shareholders are primarily institutional investors at 25.83%, followed by 1.77% insiders and 72.40% retail investors. The average institutional ownership in Sangamo Therapeutics's industry, Biotech Stocks , is 36.05%, which Sangamo Therapeutics falls below.

Who owns the most shares of Sangamo Therapeutics?

Sangamo Therapeutics’s largest shareholders are Armistice capital (40.4M shares, 11.96%), Vanguard group (12M shares, 3.94%), and Blackrock (4.7M shares, 2.61%). Together, they hold 18.51% of Sangamo Therapeutics’s total shares outstanding.

Does Blackrock own Sangamo Therapeutics?

Yes, BlackRock owns 2.61% of Sangamo Therapeutics, totaling 4.7M shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 1.69M$. In the last quarter, BlackRock decreased its holdings by -8.575M shares, a -64.58% change.

Who is Sangamo Therapeutics’s biggest shareholder by percentage of total assets invested?

Luminus management is Sangamo Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.25% of its assets in 1.68M Sangamo Therapeutics shares, valued at 415.06K$.

Who is the top mutual fund holder of Sangamo Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Sangamo Therapeutics shares, with 2.51% of its total shares outstanding invested in 5.65M Sangamo Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools